Notably, 124 (96.1%) indicated they would consider prescribing it in CKD patients without proteinuria, reflecting awareness of recent guideline updates, such as those from KDIGO 2022 and 2024 guideline updates, which recommend SGLT2 inhibitors based on eGFR thresholds rather than albuminuria status alone [16]. Here, SLC5A2 is linked to chronic kidney disease.